|

GF-CART01 Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1: 1

Top Sponsors

  • GenomeFrontier Therapeutics TW Co., Ltd.1

Indications

  • High-grade B-cell Lymphoma (HGBCL)1
  • Primary Mediastinal Large B-Cell Lymphoma-Recurrent1
  • Primary Mediastinal Large B-Cell Lymphoma-Refractory1
  • Diffuse Large B Cell Lymphoma Relapsed1
  • Diffuse Large B Cell Lymphoma Refractory1

Other1 trial

A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.